|
1
|
Senger DR, Perruzzi CA and Papadopoulos A:
Elevated expression of secreted phosphoprotein I (osteopontin, 2ar)
as a consequence of neoplastic transformation. Anticancer Res.
9:1291–1299. 1989.PubMed/NCBI
|
|
2
|
Craig AM, Smith JH and Denhardt DT:
Osteopontin, a transformation-associated cell adhesion
phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate
in mouse epidermis. J Biol Chem. 264:9682–9689. 1989.PubMed/NCBI
|
|
3
|
Weber GF, Lett GS and Haubein NC:
Osteopontin is a marker for cancer aggressiveness and patient
survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weber GF, Lett GS and Haubein NC:
Categorical meta-analysis of Osteopontin as a clinical cancer
marker. Oncol Rep. 25:433–441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He B, Mirza M and Weber GF: An osteopontin
splice variant induces anchorage independence in human breast
cancer cells. Oncogene. 25:2192–2202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Merl J, Deeg CA, Swadzba ME, Ueffing M and
Hauck SM: Identification of autoantigens in body fluids by
combining pull-downs and organic precipitations of intact immune
complexes with quantitative label-free mass spectrometry. J
Proteome Res. 12:5656–5665. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Du H, Masuko-Hongo K, Nakamura H, Xiang Y,
Bao CD, Wang XD, Chen SL, Nishioka K and Kato T: The prevalence of
autoantibodies against cartilage intermediate layer protein,
YKL-39, osteopontin, and cyclic citrullinated peptide in patients
with early-stage knee osteoarthritis: Evidence of a variety of
autoimmune processes. Rheumatol Int. 26:35–41. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakata M, Tsuruha JI, Masuko-Hongo K,
Nakamura H, Matsui T, Sudo A, Nishioka K and Kato T: Autoantibodies
to osteopontin in patients with osteoarthritis and rheumatoid
arthritis. J Rheumatol. 28:1492–1495. 2001.PubMed/NCBI
|
|
9
|
Fierabracci A, Biro PA, Yiangou Y, Mennuni
C, Luzzago A, Ludvigsson J, Cortese R and Bottazzo GF: Osteopontin
is an autoantigen of the somatostatin cells in human islets:
Identification by screening random peptide libraries with sera of
patients with insulin-dependent diabetes mellitus. Vaccine.
18:342–354. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe M, Uchida K, Nakagaki K, Kanazawa
H, Trapnell BC, Hoshino Y, Kagamu H, Yoshizawa H, Keicho N, Goto H
and Nakata K: Anti-cytokine autoantibodies are ubiquitous in
healthy individuals. FEBS Lett. 581:2017–2021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ying X, Zhao Y, Wang JL, Zhou X, Zhao J,
He CC, Guo XJ, Jin GH, Wang LJ, Zhu Q and Han SX: Serum
anti-osteopontin autoantibody as a novel diagnostic and prognostic
biomarker in patients with hepatocellular carcinoma. Oncol Rep.
32:1550–1556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tilli TM, Silva EA, Matos LC, Faget DV,
Dias BF, Vasconcelos JS, Yokosaki Y and Gimba ER: Osteopontin is a
tumor autoantigen in prostate cancer patients. Oncol Lett.
2:109–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anborgh PH, Wilson SM, Tuck AB, Winquist
E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW and Chambers
AF: New dual monoclonal ELISA for measuring plasma osteopontin as a
biomarker associated with survival in prostate cancer: Clinical
validation and comparison of multiple ELISAs. Clin Chem.
55:895–903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hartung F and Weber GF: RNA Blood levels
of osteopontin splice variants are cancer markers. Springerplus.
2:1102013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mirza M, Shaughnessy E, Hurley JK,
Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a
selective marker for breast cancer. Int J Cancer. 122:889–897.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu XM, Schneider DF, Leverson G, Chen H
and Sippel RS: Follicular variant of papillary thyroid carcinoma is
a unique clinical entity: A population-based study of 10,740 cases.
Thyroid. 23:1263–1268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghossein R and Livolsi VA: Papillary
thyroid carcinoma tall cell variant. Thyroid. 18:1179–1181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aboelnaga EM and Ahmed RA: Difference
between papillary and follicular thyroid carcinoma outcomes: An
experience from Egyptian institution. Cancer Biol Med. 12:53–59.
2015.PubMed/NCBI
|
|
19
|
Zduniak K, Agrawal A, Agrawal S, Hossain
MM, Ziolkowski P and Weber GF: Osteopontin splice variants are
differential predictors of breast cancer treatment responses. BMC
Cancer. 16:4412016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zduniak K, Ziolkowski P, Ahlin C, Agrawal
A, Agrawal S, Blomqvist C, Fjällskog ML and Weber GF: Nuclear
Osteopontin-c is a prognostic breast cancer marker. Br J Cancer.
112:729–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ashkar S, Weber GF, Panoutsakopoulou V,
Sanchirico ME, Janssen M, Zawaideh S, Rittling S, Denhardt DT,
Glimcher MJ and Cantor H: Eta-1 (Osteopontin): An early component
of type 1 (cell-mediated) immunity. Science. 287:860–864. 2000.
View Article : Google Scholar : PubMed/NCBI
|
